Again, given the observed relationships were only evident in adults with Alzheimer’s disease, we further examined how individual (versus composite) rejuvenation proteins contributed to clinical outcomes only among the Alzheimer’s disease participants (n = 35); analyses were only conducted examining cognitive performance and functional outcomes given limited sample size in Alzheimer’s disease participants with CSF NfL (n = 14). This evidence concerns the gene NEFL and early-onset autosomal dominant Alzheimer disease.